logo
Share SHARE
FONT-SIZE Plus   Neg

Verso Paper Amends Certain Terms Of Exchange Offer - Quick Facts

Verso Paper Corp. (VRS) announced that it has amended certain terms of its previously announced exchange offer and consent solicitation of two of its subsidiaries, Verso Paper Holdings LLC and Verso Paper Inc. or "Issuers", with respect to their second priority senior secured floating rate notes due 2014 or the "Old Notes".

Initially, only those holders that validly tendered their Old Notes prior to the previously scheduled early tender date on April 10, 2012, were entitled to receive the total consideration of $1,000 in principal amount of new 9.75% Secured Notes due 2019 or the "New Notes" per $1,000 in principal amount of Old Notes tendered, which includes an early tender payment of $50 per $1,000 in principal amount of Old Notes tendered.

The company said that the Issuers have now determined that all holders that validly tender their Old Notes prior to on April 24, 2012, which is the expiration date of the exchange offer and consent solicitation, will be entitled to receive the Total Consideration.

In addition, the Issuers are amending the terms of the exchange offer and consent solicitation by waiving the condition requiring receipt of tenders from holders of more than 50% of the outstanding Old Notes.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The European Union's executive arm has ordered the Irish government to recover up to 13 billion euros, or $14.5 billion, in taxes from Apple Inc. The European Commission said it has concluded that Ireland granted the U.S. tech giant undue tax benefits of up to 13 billion euros, which is illegal under EU state aid rules. Shares of Apple are down 1 percent in pre-market activity. Abercrombie & Fitch Co. (ANF) reported Tuesday a wider year-over-year net loss for the second-quarter, hurt by a impairment charge. Net sales for the quarter were down 4%, with comparable sales declined 4%. Quarterly loss was wider than their expectations, but revenues beat their' estimates. The performance of Biotech stocks thus far this month is nothing to write home about, if we were to look at it from the standpoint of the movement of the NYSE Arca Biotechnology Index. A peek at what transpired on the FDA front in August and a preview of what September holds in store for us look pertinent.
comments powered by Disqus
Follow RTT